Drugs /

herv-e tcr transduced autologous t cells

Back to Drugs List

Overview

NCI Definition [1]:
A preparation of autologous T-lymphocytes transduced with a retroviral vector encoding a T-cell receptor (TCR) sequence specific for CT-RCC-1, a tumor-associated antigen (TAA) and HLA-A11-restricted peptide encoded by human endogenous retrovirus (HERV) type E as well as a truncated CD34 chain (CD34t), with potential antineoplastic activity. Upon isolation, transduction, expansion ex vivo and re-introduction into the patient, the autologous CT-RCC-1 HERV-E-TCR-transduced-HLA-A11-restricted CD8+/CD34t+ T-cells bind to and induce selective toxicity in tumor cells expressing both the HLA-A11 allele and the CT-RCC-1 HERV-E antigen. The CD34t protein allows the transduced cells to be identified with an anti-CD34 antibody, and facilitates monitoring of the genetically modified T-cells following adoptive transfer. CT-RCC-1 HERV-E is a TAA found in a high percentage of clear cell renal cell carcinoma (ccRCC) cells.

Clinical Trials

View Clinical Trials for herv-e tcr transduced autologous t cells

Herv-e tcr transduced autologous t cells has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating herv-e tcr transduced autologous t cells, 1 is phase 1 (1 open).

HLA-A*11:01 Positive is the most frequent biomarker inclusion criterion for herv-e tcr transduced autologous t cells clinical trials.

Clear cell renal cell carcinoma is the most common disease being investigated in herv-e tcr transduced autologous t cells clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Herv-E Tcr Transduced Autologous T Cells
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating herv-e tcr transduced autologous t cells and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
autologous ct-rcc-1 herv-e-tcr-transduced-hla-a11-restricted cd8+/cd34t+ t-lymphocytes, anti-ct-rcc-1 herv-e-tcr-transduced-hla-a11-restricted autologous cd8+/cd34t+ t-cells (sy), autologous ct-rcc-1 herv-e-tcr-transduced-hla-a11-restricted cd8+/cd34t+ t-cells, autologous herv-e tcr transduced t cells
NCIT ID [1]:
C157344

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.